Anavex Life Sciences Corp.

11.77-0.2300-1.92%Vol 689.97K1Y Perf 271.61%
Apr 22nd, 2021 16:00 DELAYED
BID11.51 ASK11.94
Open12.08 Previous Close12.00
Pre-Market- After-Market-
 - -%  - -
Target Price
20.33 
Analyst Rating
Strong Buy 1.00
Potential %
72.73 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
33/33/33 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-98/-98/-98 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-98/-98/-98 
Income Ranking
 —    -
Market Cap824.26M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
34.00 
Earnings Date
6th May 2021

Today's Price Range

11.5212.25

52W Range

3.0528.70

5 Year PE Ratio Range

-6.60-10.50

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-0.25%
1 Month
-17.17%
3 Months
92.64%
6 Months
105.59%
1 Year
271.61%
3 Years
382.38%
5 Years
124.62%
10 Years
-5.08%

TickerPriceChg.Chg.%
AVXL11.77-0.2300-1.92
AAPL131.94-1.5600-1.17
GOOG2 267.92-25.3700-1.11
MSFT257.17-3.4100-1.31
XOM55.27-0.7300-1.30
WFC42.70-0.5400-1.25
JNJ165.18-1.4100-0.85
FB296.52-4.9500-1.64
GE13.410.06000.45
JPM147.37-3.1700-2.11
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.11-0.12-9.09
Q04 2020-0.13-0.1023.08
Q03 2020-0.14-0.1121.43
Q02 2020-0.14-0.1214.29
Q01 2020-0.12-0.120.00
Q04 2019--0.07-
Q03 2019-0.17-0.1417.65
Q02 2019-0.14-0.137.14
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.12-33.33Negative
6/2021 QR-0.12-33.33Negative
9/2021 FY-0.520.00-
9/2022 FY-0.57-14.00Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.12
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume689.97K
Shares Outstanding70.03M
Trades Count6.09K
Dollar Volume28.45M
Avg. Volume3.53M
Avg. Weekly Volume837.60K
Avg. Monthly Volume1.19M
Avg. Quarterly Volume4.17M

Anavex Life Sciences Corp. (NASDAQ: AVXL) stock closed at 11.77 per share at the end of the most recent trading day (a -1.92% change compared to the prior day closing price) with a volume of 690.65K shares and market capitalization of 824.26M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. Anavex Life Sciences Corp. CEO is Christopher U. Missling.

The one-year performance of Anavex Life Sciences Corp. stock is 271.61%, while year-to-date (YTD) performance is 117.96%. AVXL stock has a five-year performance of 124.62%. Its 52-week range is between 3.05 and 28.7, which gives AVXL stock a 52-week price range ratio of 34.00%

Anavex Life Sciences Corp. currently has a PE ratio of -26.20, a price-to-book (PB) ratio of 17.85, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -62.21%, a ROC of -76.23% and a ROE of -73.88%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Anavex Life Sciences Corp., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. Anavex Life Sciences Corp.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Anavex Life Sciences Corp. is Strong Buy (1), with a target price of $20.33, which is +72.73% compared to the current price. The earnings rating for Anavex Life Sciences Corp. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Anavex Life Sciences Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Anavex Life Sciences Corp. has a Neutral technical analysis rating based on Technical Indicators (ADX : 41.61, ATR14 : 1.25, CCI20 : -100.58, Chaikin Money Flow : -0.06, MACD : 0.21, Money Flow Index : 19.20, ROC : -22.00, RSI : 40.33, STOCH (14,3) : 16.77, STOCH RSI : 0.53, UO : 40.31, Williams %R : -83.23), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Anavex Life Sciences Corp. in the last 12-months were: Elliot Favus (Option Excercise at a value of $445 390), Elliot Favus (Sold 145 500 shares of value $1 841 855 ), Peter Donhauser (Buy at a value of $14 760)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.

CEO: Christopher U. Missling

Telephone: +1 844 689-3939

Address: 51 West 52nd Street, New York 10019, NY, US

Number of employees: 20

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

60%40%

Bearish Bullish

48%52%

Bearish Bullish

61%39%

News

Stocktwits